It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

providing additional therapies for those who do become hospitalised is an important step in combating this pandemic," said Patrizia Cavazzoni, director of the FDA's Centre for Drug Evaluation and ...

The FDA published it three days later, on the 28th. The recalled products include 8-ounce packages of La Fiesta brand "Unseasoned Bread Crumbs (Pan Rayado)" and "Seasoned Bread Crumbs (Pan Rayado ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...

The drug is for moderate to severe acute pain. The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe ...

The company also operates an online store. In the Jan. 29 weekly enforcement report, the FDA classified the recall of eight Cal Yee Farm products as a "Class I" designation. A "Class I" recall is ...

“This action and the agency’s designations to expedite the drug’s development and review underscore FDA’s commitment to approving safe and effective alternatives to opioids for pain ...

For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug ...

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. For the first time in over two decades, the U.S. Food and Drug Administration (FDA) has ...

“Today’s approval is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, the acting director of the FDA's Center for Drug Evaluation and ...